SPAGO — Spago Nanomedical AB (publ) Income Statement
0.000.00%
Last trade - 00:00
- SEK78.20m
- SEK45.95m
- SEK1.20m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | SAS | SAS | SAS | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.03 | 0.342 | 0.66 | 1.05 | 1.2 |
Cost of Revenue | |||||
Gross Profit | 18.2 | 6.11 | 4.92 | 4.75 | — |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 20.2 | 19.3 | 39.9 | 40.5 | 44.3 |
Operating Profit | -20.2 | -19 | -39.2 | -39.5 | -43.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -20.2 | -18.9 | -39.1 | -39.2 | -42.2 |
Net Income After Taxes | -20.2 | -18.9 | -39.1 | -39.2 | -42.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -20.2 | -18.9 | -39.1 | -39.2 | -42.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -20.2 | -18.9 | -39.1 | -39.2 | -42.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.898 | -0.653 | -0.934 | -0.587 | -0.431 |
Dividends per Share |